Effect of eradication of Helicobacter pylori on serum pepsinogen I, gastrin, and insulin in duodenal ulcer patients: a 12-month follow-up study

Am J Gastroenterol. 1994 Sep;89(9):1511-4.

Abstract

Objectives: To understand the short-term and long-term effects of the eradication of Helicobacter pylori on serum pepsinogen I, gastrin, and insulin concentration, we studied 53 patients with endoscopically proven duodenal ulceration and H. pylori infection.

Methods: All patients received a 2-wk course of colloidal bismuth subcitrate, amoxycillin, and metronidazole, and endoscopy was performed at 1.5, 3, 6, and 12 months after entry. H. pylori status was assessed by a urease test and histology.

Results: Among 43 patients in whom H. pylori was eradicated throughout the follow-up year, the mean basal pepsinogen I was 108 ng/ml at pretreatment, decreasing significantly to 85, 77, 80, and 75 ng/ml at 1.5, 3, 6, and 12 months, respectively, at posttreatment. The basal gastrin was 100 pg/ml at pretreatment and fell significantly to 72, 64, 65, and 59 pg/ml, respectively, posttreatment. Of the four patients in whom the H. pylori was not eradicated, there was no significant change in the median basal pepsinogen I and gastrin concentration. Among the six patients in whom the H. pylori was again detectable within the follow-up year, the fallen serum concentration of pepsinogen I and gastrin returned to the pretreatment level. There was no significant change of basal insulin concentration after triple therapy in either the successfully eradicated or failed group.

Conclusion: We conclude that H. pylori is the leading and direct cause of higher serum concentration of pepsinogen I and gastrin in duodenal ulcer patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amoxicillin / therapeutic use
  • Anti-Ulcer Agents / therapeutic use
  • Bismuth / therapeutic use
  • Drug Therapy, Combination
  • Duodenal Ulcer / blood*
  • Duodenal Ulcer / epidemiology
  • Duodenal Ulcer / microbiology*
  • Female
  • Follow-Up Studies
  • Gastrins / blood*
  • Helicobacter Infections / drug therapy*
  • Helicobacter Infections / epidemiology
  • Helicobacter pylori / isolation & purification*
  • Humans
  • Insulin / blood*
  • Male
  • Metronidazole / therapeutic use
  • Middle Aged
  • Organometallic Compounds / therapeutic use
  • Pepsinogens / blood*
  • Time Factors

Substances

  • Anti-Ulcer Agents
  • Gastrins
  • Insulin
  • Organometallic Compounds
  • Pepsinogens
  • Metronidazole
  • gastrin 17
  • Amoxicillin
  • bismuth tripotassium dicitrate
  • Bismuth